| Literature DB >> 21753887 |
Somchai Amornyotin1, Udom Kachintorn, Wiyada Chalayonnawin, Siriporn Kongphlay.
Abstract
INTRODUCTION: The aim of this study was to evaluate and compare the clinical efficacy of propofol-based deep sedation (PBDS) for endoscopic retrograde cholangiopancreatography (ERCP) procedure in sick (American Society of Anesthesiologists [ASA] physical status III-IV) and nonsick (ASA physical status I-II) elderly patients in a teaching hospital in Thailand.Entities:
Keywords: American Society of Anesthesiologists (ASA); deep sedation; developing country; elderly; endoscopic retrograde cholangiopancreatography; propofol (ERCP); sick
Year: 2011 PMID: 21753887 PMCID: PMC3132095 DOI: 10.2147/TCRM.S21519
Source DB: PubMed Journal: Ther Clin Risk Manag ISSN: 1176-6336 Impact factor: 2.423
Characteristics of patients, duration of procedure, and indications of procedure
| Age (year) (mean, SD) | 63.3 (15.0) | 75.1 (9.6) | 0.211 |
| Gender (n, %): Male | 52 (47.7) | 25 (52.0) | 0.700 |
| Female | 57 (52.3) | 24 (49.0) | |
| Weight (kg) (mean, SD) | 56.1 (11.3) | 55.4 (10.8) | 0.427 |
| ASA physical status (n, %) | <0001 | ||
| I–II | 109 (100.0) | 0 | |
| III–IV | 0 | 49 (100.0) | |
| Duration of procedure (minutes) (mean, SD) | 35.7 (19.3) | 38.5 (25.3) | 0.063 |
| Indications (n, %) | 0.665 | ||
| Cholelithiasis | 59 (54.1) | 23 (47.0) | |
| Hepatobiliary tract tumor | 31 (28.5) | 17 (34.7) | |
| Biliary tract stricture | 11 (10.1) | 5 (10.2) | |
| Others | 8 (7.3) | 3 (6.1) |
Notes: Group A: ASA physical status I–II; Group B: ASA physical status III–IV.
Considered to be statistically significant.
Abbreviations: ASA, American Society of Anesthesiologists; SD, standard deviation.
Success rate and sedative/analgesic agents used in both groups
| Success rate (n, %) | 101 (92.7) | 46 (93.9) | 0.781 |
| Fentanyl | |||
| mg/kg | 0.001 (0.000) | 0.001 (0.000) | 0.717 |
| mg/kg/h | 0.002 (0.001) | 0.002 (0.001) | 0.139 |
| Propofol | |||
| mg/kg | 3.87 (2.47) | 3.20 (1.94) | 0.210 |
| mg/kg/h | 7.00 (3.84) | 5.89 (3.40) | 0.100 |
| Midazolam | |||
| mg/kg | 0.03 (0.01) | 0.02 (0.01) | 0.297 |
| mg/kg/h | 0.06 (0.05) | 0.05 (0.04) | 0.167 |
Notes: Group A: ASA physical status I–II; Group B: ASA physical status III–IV.
Abbreviation: SD, standard deviation.
Sedation-related adverse events (n, %)
| Overall | 29 (26.6) | 14 (28.6) | 0.797 |
| Respiratory | 6 (5.5) | 2 (4.1) | 0.706 |
| Hypoxia | |||
| (SpO2 < 90%) | 2 (1.8) | 1 (2.0) | 0.930 |
| Upper airway obstruction | 4 (3.7) | 1 (2.0) | 0.589 |
| Cardiovascular | 23 (21.1) | 12 (24.5) | 0.635 |
| Hypotension | 20 (18.3) | 12 (24.5) | 0.374 |
| Bradycardia | 3 (2.8) | 0 | 0.241 |
Notes: Group A: ASA physical status I–II; Group B: ASA physical status III–IV.
Abbreviation: SpO2, oxygen saturation.